Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. 25202099 2014
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing. 24419427 2014
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 22357254 2012
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 Biomarker disease BEFREE KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, while also serving as a predictor of prognosis for TETs. 22938452 2012
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Considering the need to treat advanced TC more effectively, disparate findings in predictive molecular markers (eg, KIT mutations in TSCC, but not in thymomas) suggest that targeted treatments will have to be different in thymomas and TC. 21070984 2011
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. 20970876 2011
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 Biomarker disease BEFREE Apart from their different morphology, TC and thymomas differ also in functional terms (TC, in contrast to thymomas, have lost the capacity to promote the maturation of intratumorous lymphocytes), have different genetic features (discussed in this review), a different immunoprofile (most TC overexpress c-KIT, whereas thymomas are consistently negative), and different clinical features (TC, in contrast to thymomas, are not associated with paraneoplastic myasthenia gravis). 20859121 2010
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 GeneticVariation disease BEFREE Mutations in the kit gene have been related to response to imatinib in gastrointestinal stromal tumor and one case report of thymic carcinoma. 20651610 2010
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 AlteredExpression disease BEFREE The clinical relevance of KIT mutations is more limited in thymic carcinoma than in GIST as KIT mutations are far less frequent (7% of thymic carcinomas) and are not correlated with KIT expression; furthermore, KIT mutants are not uniformly sensitive to imatinib. 20859122 2010
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 AlteredExpression disease BEFREE Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. 20197733 2009
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 AlteredExpression disease BEFREE KIT protein was expressed in 88% of the thymic carcinomas and 0% of the thymomas. 18448188 2008
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 Biomarker disease BEFREE KIT- and CD5-positive staining was observed only in thymic carcinoma. 18486988 2008
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 Biomarker disease BEFREE In summary, COX-2 is expressed in all subtypes of thymomas and thymic carcinomas and thus represents, in addition to EGFR and KIT, a potential therapeutic target. 16823844 2006
CUI: C0205969
Disease: Thymic Carcinoma
Thymic Carcinoma
0.400 CausalMutation disease CGI